RNA‐Seq and rescue experiments revealed that HBM‐Exo inhibited IL‐17 signalling pathway, as well as downstream target FADD, thereby inhibiting cell apoptosis, so as to repair AT‐II cell damage, consequently preventing and treating BPD. The gene discussed is IL17A; the disease is bronchopulmonary dysplasia.